Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study.

Agnese PaderiSara Fancelli Enrico Caliman Serena PillozziElisabetta GambaleMarinella Micol MelaLaura DoniFrancesca MazzoniLorenzo Antonuzzo

Published in: Current oncology (Toronto, Ont.) (2021)

Our findings suggest that treatment with ICIs in elderly populations is safe and feasible. Patients over 70 years are more prone to develop skin irAEs, while younger patients are more subject to experience endocrine toxicities.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
patient reported outcomes